Compare Incyte Corporation (INCY) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Illinois Tool Works Inc. — how do they compare? Incyte Corporation trades at $112.91 (market cap $22.85B), while Illinois Tool Works Inc. trades at $262.99 (market cap $74.38B). The key difference: Illinois Tool Works Inc. is far larger — about 3.3× Incyte Corporation's market cap, and Illinois Tool Works Inc. pays a 2.63% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Illinois Tool Works Inc. for 67 Days on average.
| INCY | ITW | |
|---|---|---|
Market Cap | $22.85B | $74.38B |
Volume | 1,927,029 | 1,125,477 |
Sector | Health | Industrials |
52-Week High | $129.93 | $299.60 |
52-Week Low | $83.80 | $241.07 |
Typical Hold Time | 33 Days | 67 Days |
Enterprise Value | $18.35B | $83.23B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
ITW trades at $261.15, down 2.24% on the day, with technical indicators showing bearish momentum as the stock tests support near $261. The company maintains strong fundamentals with a 19.39% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights ITW's dividend increase to $1.72 per share, reinforcing its status as a Dividend King with 59 years of consecutive increases.
The outlook remains mixed with solid profitability offset by bearish technicals. Upside potential exists toward the $276.86 analyst consensus target, but investors face headwinds from weak technical momentum and mixed analyst sentiment where only 21% recommend buying. Key risks include debt levels rising to 55.54% of assets and exposure to cyclical industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
